Modified EC7 Cells for High Titer Adenovirus Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant viruses, particularly adenovirus type 5, face challenges in achieving high titers and consistent production due to limitations in virus-host interaction, such as the absence of the Coxsackie and Adenovirus receptor (CXADR) in certain cells, leading to inefficient transduction and variable viral yields.
Innovation Solution
Genetically modifying host cells, such as CHO or EC7 cells, to express CXADR and employ recombinant entities like transcriptional repressors or siRNA to reduce viral payload gene expression, allowing for the production of high titers of recombinant adenovirus type 5 viruses with predictable and reproducible results.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If host cells are genetically modified to express CXADR to improve virus entry, then transduction efficiency is improved, but viral payload gene expression increases causing cellular toxicity
Solution Approach 1:
The patent applies preliminary action by genetically modifying host cells to express CXADR before viral infection, ensuring efficient virus entry. The cellular machinery is pre-prepared to handle viral payload through co-expression of viral proteins, preventing toxicity before it occurs.
Solution Approach 2:
The patent uses viral proteins as intermediaries that are co-expressed with the viral payload. These intermediary proteins mediate the interaction between the viral payload and cellular machinery, reducing toxic effects while maintaining productivity.
2Quantity of substance
If viral payload gene expression is increased to improve therapeutic effect, then therapeutic efficacy is improved, but cellular toxicity increases
Solution Approach 1:
Viral proteins serve as intermediaries that facilitate the expression of high levels of therapeutic payload while protecting the cell from toxicity. These intermediary proteins mediate the interaction between the payload and cellular systems.
Solution Approach 2:
The patent changes the parameter of viral protein expression by co-expressing multiple viral proteins simultaneously. This parameter change allows the system to tolerate higher payload expression levels without cellular toxicity.
3Quantity of substance
If high quantities of recombinant viruses are produced to meet therapeutic requirements, then viral titer is improved, but production consistency deteriorates
Solution Approach 1:
The patent changes multiple parameters simultaneously: expressing CXADR to improve entry efficiency, co-expressing viral proteins to reduce toxicity, and optimizing culture conditions. This multi-parameter approach enables consistent high-titer production.
Solution Approach 2:
The system incorporates feedback mechanisms where the expression of viral proteins and CXADR creates a favorable environment that consistently supports high viral production. The cellular environment is conditioned to feedback positively to viral replication.
Data Source
AI summary
Recombinant cells and methods therefor are contemplated that allow for rapid and high titer production of recombinant viruses, and especially replication deficient Ad5 virus. In some preferred aspects, the host cell is modified to produce an inhibitor that reduces or eliminates the expression of a therapeutic protein encoded in the virus, while in other aspects, the virus includes a gene that directly or indirectly reduces or eliminates the expression of a therapeutic protein encoded in the virus. Most preferably, shRNA encoded by the host cell will reduce or suppress expression of a payload gene encoded in the recombinant virus.